The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling

The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling

Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid tumors, such as non‐small cell lung cancer (NSCL...

Full description

Bibliographic Details
Main Authors: Bo Zhang, Linling Wang, Qi Zhang, Youyou Yan, Hong Jiang, Runlei Hu, Xinglu Zhou, Xingguo Liu, Jianguo Feng, Nengming Lin
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Molecular Oncology
Subjects:
ABT‐199
Ibr‐7
ibrutinib
mTORC1, S6
non‐small cell lung cancer
Online Access:https://doi.org/10.1002/1878-0261.12454

Internet

https://doi.org/10.1002/1878-0261.12454

Similar Items